Joseph D. Jackson, PhD, MS
Philadelphia, PA 19107
(215) 923-7583 fax
Most Recent Peer-reviewed Publications
- Economic evaluations alongside effectiveness trials
- Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: Results from the CHARISMA trial
- Long-term cost-effectiveness of clopidogrel in STEMI patients
- The risk of cardiovascular events in primary care patients following an episode of severe hypertension
- FDAMA 1997 section 114: Another look
MS;PhD - University of Mississippi, School of Pharmacy, Oxford, Mississippi
Department of Health Education and Welfare, Health Services Administration and National Institute of Mental Health
Research and Clinical Interests
Outcomes Research, Cost-Effectiveness, Patient-Reported Outcomes, Comparative Effectiveness Research
Dr. Jackson has 30 years of experience in the pharmaceutical industry, 25 of which have been spent in clinical research. His work has involved many facets of the management and practice of Outcomes Research, including the translation of clinical evidence into user-friendly cost-effectiveness models concerning parenteral antibiotic therapy (cefotaxime), anticoagulant therapy for stroke prevention (warfarin), lipid management (pravastatin), hypertension management (losartan, irbesartan, omapatrilat), atherothrombosis (clopidogrel) and anticoagulation (apixaban) therapies for cardiovascular event prevention. He has generated Quality of Life evidence, and obtained listing in the package insert for a Patient-Reported Outcomes claim (eflornithine) in the USA and Europe. During his career he has been associated with numerous market access filings in multiple therapeutic areas for Health Technology Assessment reviews, including three Section 114 filings with the FDA in the USA and multiple NICE filings in the UK. He has served in leadership roles related to Outcomes Research in ISPOR, SMDM, PhRMA and NPC.
In his current role, Dr. Jackson provides direction for the Jefferson School of Population Health's Master of Science degree program in Applied Health Economics and Outcomes Research (MS-AHEOR) and for the AHEOR specialization in the School's PhD program in Population Health Sciences. These programs ground students in the fundamentals of AHEOR, with emphasis on applications to everyday work settings. Students learn the dimensions of evidence-based value packages to support prudent resource allocation of goods and services in health care. The MS-AHEOR and PhD specialization build on Jefferson's experience and expertise in clinical excellence and aim to provide students with the knowledge of outcomes research, comparative effectiveness and incremental economic value assessments of health care interventions.